螺内酯对高原性心脏病伴心力衰竭患者6min步行试验的影响及安全性评价

Impacts and Safety Evaluation of Aldactone on Six-minute Walk Test Performance in Patients with High Altitude Heart Disease and Heart Failure

目的:探讨螺内酯对高原性心脏病(HAHD)伴心力衰竭患者6min步行试验的影响及安全性评价。方法:选择2004年2月～2009年6月住院的HAHD患者41例,随机分为治疗组21例,对照组20例。2组均给予卡托普利、速尿、地高辛等药物。治疗组再加螺内酯40～60mg·d-1。2组均治疗3个月。结果:与治疗前比较,2组治疗后均使6min步行距离增加(P<0.01);2组治疗后比较,治疗组优于对照组(P<0.01)。2组毒副反应组间比较无显著性差异(P>0.05)。结论:螺内酯治疗对HAHD患者心功能的改善有益,可提高患者的运动能力及生活质量,短期应用螺内酯是安全的。

OBJECTIVE： To study the impacts and safety evaluation of aldactone on six-minute walk test performance in patients with high altitude heart disease and heart failure. METHODS： 41 inpatients with high altitude heart disease from Feb. 2004 to Jun. 2009 were randomly divided into treatment group （n= 21） and control group （n=20）. Both groups were given captopril, furosemide and digoxin, etc. for three months. Treatment group were additionally treated with aldactone （40-60 mg·d^-1）. RESULTS： The six-minute walking distances were increased in two groups after the treatment （P〈0.01）. Treatment group was better than control group in the curative effect （P〈0.01）. No significant difference was noted in drug toxicity between two groups （P〉0.05）. CONCLUSION： Aldactone shows sound effect on improvement of heart functions in patients with high altitude heart disease, at the same time it can improve motor functions and life quality of patients. So it is safe to administer aldactone in a short period.